Tagged with Portugal

Portugal Portugal’s strong legal framework along with its low production costs and strategic location within Europe have given rise to a thriving medicinal cannabis sector. With exports in 2022 that surpassed the previous year by 63 percent and an increasing number of companies licensed for cultivation and manufacturing, the country is…

Portugal Erstwhile 21-year CEO of leading Portuguese generics group Tecnimede, Maria do Carmo Neves today serves as president of her country’s generics industry association, APOGEN. She outlines the highly challenging market situation facing generics, biosimilar, and value-added medicine producers in Portugal today; how this situation reflects Europe-wide trends; and the solutions…

Portugal Speaking from Servier’s new open-plan office in Lisbon, a space aimed at promoting cross-functional integration and “collective intelligence,” experienced industry executive Frédéric Bengold looks back on three successful years at the helm of Servier Portugal and outlines his goals for the future. With a refreshed global visual identity and corporate…

Portugal P-BIO, Portugal’s leading association for its biotech industry, is approaching a quarter century in existence. Its president, Simão Soares, tells PharmaBoardroom that there has been “substantial positive change” in the country’s biotech environment in these years, and – while the overall industry is still relatively modest in size compared to…

Portugal One of Europe’s smaller nations and its westernmost, Portugal, with a pharma market worth roughly USD 3.5 billion, may not be known as the continent’s pharma powerhouse. Yet the country boasts plenty of impressive credentials —such as a national healthcare system (NHS) that is not only universal and free, but…

Portugal Part of PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown on post-market approval processes and regulations in Portugal. Buy The Pharma Legal Handbook: Market Access & HTA – Portugal here for £359.   What are the pricing principles and processes in your…

Italy Guerbet’s Alessandro Bocci – General Manager Italy & Iberia – describes the nearly 100-year-old company’s firm position in the field of contrast media for radiology and its plans for developing a portfolio in artificial intelligence (AI). In addition, he outlines how the Italy, Spain and Portugal cluster made its way…

Spain Kyowa Kirin’s head of the South Europe cluster, Norberto Villarrasa, explains the Japanese company’s presence in Spain, its focus on rare diseases and onco-haematology, and comments on the challenges around access to rare disease treatments. In addition, the executive provides the company’s view on the potential and advantages of risk-sharing…

Europe In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global market access & pricing strategic planning at Merck Group, casts his eye across Europe to assess how sustainability criteria are…

Pharma Legal Handbook Key legal info on biosimilars & biologics in Portugal. Prepared in association with Cuatrecasas, a leading Iberian law firm, this is an extract from The Pharma Legal Handbook: Portugal, available to purchase here for GBP 99.     1. Are biosimilar medicines considered the same as generic medicines in your…

Pharma Legal Handbook Want to know more about localization in Portugal? Prepared in association with Cuatrecasas, a leading Iberian law firm, this is an extract from The Pharma Legal Handbook: Portugal, available to purchase here for GBP 99.     1. Are there any rules or regulations requiring and/or encouraging localization in your…

Pharma Legal Handbook An intro to the legal situation for orphan drugs and rare diseases in Portugal. Prepared in association with Cuatrecasas, a leading Iberian law firm, this is an extract from The Pharma Legal Handbook: Portugal, available to purchase here for GBP 99.     1. What is the definition of Rare…